Latest: Drugs with margins already under 30% won't get cheaper; Supreme Court hearing due October 27
The NPPA has capped trade margins at 30% of MRP (excluding GST) on 137 non-scheduled anti-cancer drugs, with revised prices from November 9, the Ministry of Chemicals and Fertilisers said. Prices could fall by up to 70%, though drugs whose margins are already below 30% will not get cheaper; manufacturers must report revised prices and maintain supply, hospitals and pharmacies must display them, and the move follows Supreme Court hearings on non-scheduled drug prices, with the next one on October 27. Summary updated 19 Oct, 02:16 IST
Why it matters: Cancer treatment is a major cause of household medical spending in India, so lower drug prices could ease costs for patients and families.
New developments are added here, newest first. When the headline, summary or other sections change, the earlier version is kept under “See earlier version”.
Summary before this update: The NPPA has capped trade margins at 30% of MRP on 137 non-scheduled anti-cancer drugs, with revised prices from November 9, the Ministry of Chemicals and Fertilisers said. Prices could fall by up to 70%; manufacturers must publish revised price lists and maintain supply, hospitals and retailers must display the new prices, and state drug controllers will ensure compliance. One report says the move followed a Supreme Court nudge on the gap between retailer price and MRP.
Note before this update: Coverage is broadly consistent and mostly neutral; outlets differ mainly in which figures, procedural details and background (such as the Supreme Court nudge) they include.
“What's missing” before this update:
Based on 9 articles read in full. Scores describe each article's framing, not the outlet and not whether it is accurate.
Large outlets read: 4 of 15 (Times of India, Hindustan Times, The Hindu, Jagran).
Coverage is broadly consistent and mostly neutral or mildly supportive; outlets differ mainly in which figures, procedural details and background (such as the Supreme Court case) they include.
No real disagreement between sides in this coverage.
Why: State-led price regulation to cut drug costs and protect patients is a welfare, statist frame. Mostly relays government figures without strong loaded language, so the lean is modest.
Why: Plain report of a price-control order; touches state-led welfare and regulation of markets slightly, with no loaded language or critics quoted. Mild statist lean, so near-centre.
Why: Plain report of a price-regulation announcement; state-led welfare measure leans slightly left on statism, but wording is neutral and no religion or social-justice angle appears.
Why: Reports a price-regulation step for affordability; mild welfare/state-intervention lean, but wording is plain and relays the ministry. No religion or identity angle, so the score stays near centre.
Why: Price caps on cancer drugs are a state-led welfare and affordability measure (statism, left), but the report is short, plain and neutral in tone, so the score is mild.
Why: Reports a state price-control measure for cancer drugs with a welfare and affordability angle, which leans slightly left on statism. Sourcing is balanced and the tone is explanatory, so it stays near centre.
Why: State price regulation to make cancer drugs affordable is a welfare, state-led intervention, giving a mild left lean on statism. Tone is plain and relays an official statement without praise.
Why: Frames state price regulation of cancer drugs as good news for patients; welfare and state-led market intervention with little industry pushback, though largely a factual regulatory report.
Why: Frames price cap as welfare relief for patients; state-led price regulation of private trade margins fits the statism dimension (left). No religion or social-justice angle; mild intensity.
Critical, Neutral or Supportive, scored separately. It refers to the Union government unless the story is about a state. On the spectrum strip, each dot is an article: its position is the ideology score and its colour is the stance.
If an article would score differently with the parties' roles reversed, that signal is partisanship. It goes into the stance tag, not the ideology score.
High, Medium or Low, based on how much of the article was read, how many clear signals it has, and whether they agree.
Stories with fewer than five articles are marked. A blindspot is a contested story where we found coverage from only one side.
Articles that touch none of the three dimensions, such as a car launch or a match report, carry no ideology score.
This prototype is refreshed by hand (last on 17 Oct, 03:00 IST). At launch:
| Wires and the top 20 outlets | checked every 5 minutes |
| All other outlets | checked every 15 minutes |
| New story | goes up at 3 articles from 2 or more outlets, marked Limited coverage |
| Live stories | new articles added every 15 minutes; summary rewritten at most hourly |
| Home page order | every 15 minutes |
New facts go into a dated update log at the top of the story. New articles carry an “Added” tag. If a note or list changes, the earlier version stays viewable.
A story is Live while coverage arrives, Winding down after about 2 days without new coverage, and Archived after about 7. Nothing is deleted: links never change, archived scores are frozen, and stories stay on their issue pages and in search.
NDTV, India Today, Times of India, Hindustan Times, The Hindu, Indian Express, News18, ABP, Times Now and Mint block the reader used for this prototype, so their articles are missing. Each story shows how many of India’s 15 largest outlets we read. The launch pipeline will read outlets’ public feeds, TV transcripts and Hindi articles.
Editor-in-charge: [name to be added before launch]. Grievance officer under the IT Rules, 2021: [name and contact to be added before launch]. Complaints are acknowledged within 24 hours and resolved within 15 days.
[Who owns and funds Nazariya, to be published before launch]. Nazariya will list every funder and will not accept money from any political party.
Anyone, including the outlet that published an article, can appeal a score: tap any score on a story page, then "Appeal this score" to write to the editor. Outlets can also dispute a summary. The editor reviews every appeal, and any change is recorded below. Appeals: [appeals email to be added before launch].
No detail that could identify a child or a survivor of sexual violence (Juvenile Justice Act, POCSO, BNS section 72). Court cases are reported as what was said and alleged. No analysis of a poll in the 48 hours before voting there (Representation of the People Act, section 126). Press Council and NBDSA norms on communal incidents.